Literature DB >> 1050385

Antibiotic susceptibilities of streptococci from the mouth and blood of patients treated with penicillin or lincomycin and clindamycin.

I Phillips, C Warren, J M Harrison, P Sharples, L C Ball, M T Parker.   

Abstract

Patients undergoing dental extractions were non-randomly allocated to three groups, one of which received no antibiotic, one benzylpenicillin followed by oral penicillin for 5 days, and the third intramuscular lincomycin followed by oral clindamycin. Dental extraction was performed at the beginning of the course of chemotherapy. Streptococci were isolated from the extracted teeth, from blood cultures collected before and immediately after dental extraction, and from sutures removed from the gums 5-7 days after the operation. The species of these organisms was determined, and their susceptibilities to penicillin, clindamycin, cephaloridine, erythromycin and tetracycline were assessed. The majority of streptococci isolated from teeth belonged to the species Streptococcus sanguis, S. mitior, S. mutans and S. milleri. Occasional isolates of each of these organisms collected before the antibiotic could take effect were resistant to penicillin. Three of these species, but not S. mutans, were the commonest streptococci to be isolated from the blood after dental extraction. Penicillin completely suppressed dental bacteriaemia under the conditions of our investigation, and lincomycin reduced the incidence by about 60 per cent. The commonest streptococci from sutures were also S. sanguis, S. mitior, S. mutans and S. milleri. S. faecalis was also isolated, but only in patients who had received antibiotics. Among the non-faecalis organisms, penicillin resistance was significantly more frequent among isolates from patients given penicillin than from patients not given this antibiotic, and clindamycin resistance was significantly more frequent among isolates from patients given lincomycin and clindamycin than from patients not given these antibiotics.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1050385     DOI: 10.1099/00222615-9-4-393

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  13 in total

Review 1.  Streptococcus milleri group: renewed interest in an elusive pathogen.

Authors:  S C Piscitelli; J Shwed; P Schreckenberger; L H Danziger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-06       Impact factor: 3.267

2.  Streptococcus mutans endocarditis.

Authors:  J Moore; C T Keane; G H Tomkin
Journal:  Ir J Med Sci       Date:  1977-05       Impact factor: 1.568

3.  In vitro antimicrobial inhibition patterns of nutritionally variant streptococci.

Authors:  R C Cooksey; J M Swenson
Journal:  Antimicrob Agents Chemother       Date:  1979-10       Impact factor: 5.191

4.  Occurrence and cultural features of Streptococcus milleri in various body sites.

Authors:  P M Poole; G Wilson
Journal:  J Clin Pathol       Date:  1979-08       Impact factor: 3.411

5.  The isolation of streptococci from human faeces.

Authors:  P F Unsworth
Journal:  J Hyg (Lond)       Date:  1980-08

6.  Infections caused by group F streptococci.

Authors:  J Righter; J Zwerver
Journal:  Can Med Assoc J       Date:  1981-11-01       Impact factor: 8.262

7.  Hyaluronidase production in Streptococcus milleri in relation to infection.

Authors:  P F Unsworth
Journal:  J Clin Pathol       Date:  1989-05       Impact factor: 3.411

8.  Resistance to penicillin-streptomycin synergy among clinical isolates of viridans streptococci.

Authors:  B F Farber; G M Eliopoulos; J I Ward; K Ruoff; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

9.  The cultural and biochemical characters of Streptococcus milleri strains isolated from human sources.

Authors:  L C Ball; M T Parker
Journal:  J Hyg (Lond)       Date:  1979-02

10.  Purification and immunochemical studies of type b carbohydrate antigen of oral Streptococcus milleri.

Authors:  T Yakushiji; M Inoue; T Koga
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.